Volume 8 Supplement 2

Anemia in Critical Care: Etiology, Treatment and Prevention

Open Access

Alternatives to blood in the 21st century

Critical Care20048(Suppl 2):S15

https://doi.org/10.1186/cc2412

Published: 14 June 2004

Abstract

Persons who suffer traumatic injury are likely to be transfused with considerable amounts of blood during initial resuscitation efforts. Oxygen-carrying solutions are currently in clinical testing as substitutes for red blood cells. Although these agents may eliminate many concerns associated with blood administration (short shelf life, infectious and immunologic risks, the need to type and cross-match), early cell-free hemoglobin solutions demonstrated nephrotoxicity and were associated with pulmonary and systemic hypertension, among other adverse events. Newer polymerized hemoglobin solutions show acceptable safety profiles in the surgical setting and studies are being designed, some with funding from the US Department of Defense, to evaluate their efficacy in hemorrhaging trauma victims.

Keywords

blood substitutes hemorrhage injury trauma

Injuries lead to a loss of more years of productivity than do cancer and heart disease combined. More than 150 000 people die each year in the USA as a result of trauma [1]. Hemorrhagic shock remains a major problem [2], occurring in about 15% of trauma patients, and the mortality rate is 50% in this group. Unfortunately, replacement blood is often not available in the setting of traumatic hemorrhage because of the paucity of universal donor-type blood, the length of time required for type and cross-matching, and the limited blood bank inventory secondary to the short shelf life of red blood cells (RBCs) [3]. In addition, large volumes of transfusions are given only reluctantly because of concerns about transmission of viruses and the potentially immunosuppressive nature of blood. Use of an alternative resuscitation fluid, which functions both as a volume expander and an oxygen-carrying fluid, may lead to improved outcomes in the critically injured [4].

A variety of new agents are in phase III efficacy trials and offer potential benefits when used for fluid replacement and as oxygen therapeutic solutions [4]. These products have a long shelf life, do not require type and cross-matching, are free of viral or bacterial contamination, have a much lower viscosity than blood, and may lack the immunosuppressive activity of blood. Hemoglobin-based RBC substitutes have been shown to have efficient oxygen transport properties. Safety remains a concern, however, because early cell-free hemoglobin preparations demonstrated significant nephrotoxicity [5]. Some of these solutions have been associated with pulmonary and systemic hypertension [6], decreased cardiac output, and decreased splanchnic perfusion, presumably mediated by a nitric oxide scavenging effect [7]. Cross-linking and polymerizing hemoglobin subunits have reduced the incidence of nephrotoxicity, but unwanted pressor effects have remained problematic [4].

Recent studies have evaluated the utility of ultrapurified polymerized bovine hemoglobin (HBOC-201) as an oxygen-carrying blood substitute [8]. Bovine hemoglobin administration has been well tolerated in humans and improves oxygen delivery when compared with crystalloid infusion [9]. Phase III trials with this product in elective orthopedic surgery were recently completed. Prehospital and emergency center trauma trials have been initiated in conjunction with the US Department of Defense.

Promising research efforts by Northfield Laboratories (Evanston, IL, USA) have centered on polymerized, pyridoxylated, stroma-free human hemoglobin [4]. Polymerized hemoglobin and banked RBCs have similar oxygen transport and oncotic characteristics. In addition, this polymerized hemoglobin does not appear to cause pulmonary or systemic hypertension [10]. In a randomized prospective study of 44 trauma victims, Gould and coworkers [3] found a reduced blood transfusion requirement in patients receiving up to 6 units (300 g) of polymerized hemoglobin during resuscitation (6.8 units versus 10.4 units of packed RBCs in control individuals) through day 1. No adverse effects related to polymerized hemoglobin infusion were observed during the study. Phase III trials in elective vascular and general surgery are ongoing. A prehospital trauma trial has also been initiated in conjunction with the US Department of Defense with this product.

The Canadian Department of National Defense is investigating an RBC substitute, namely HemoLink™ (Hemosol Inc., Mississauga, Ontario, Canada), which is an oligimeric hemoglobin solution derived from outdated human blood. After completing myriad preclinical and phase I safety trials, Hemosol Inc. initiated four controlled randomized surgical (orthopedic and cardiac) phase II studies focusing on both safety and avoidance of transfusion [4]. The company has not reported significant adverse effects. No published data from the two clinical trials are currently available. A pivotal phase III multicenter trial in coronary bypass patients was recently completed in Canada and the UK.

Perfluorochemical emulsions (e.g. Fluosol-DA) initially appeared promising because of their ability to carry large amounts of dissolved oxygen. Unfortunately, clinical trials showed a lack of effectiveness in the treatment of severe anemia due to hemorrhage [11]. The second generation of perfluorocarbons appears highly promising for use in isovolemic hemodilution [12], but phase III trials utilizing perflubron – the latest perfluorocarbon – in the setting of cardiac surgery were recently terminated.

In conclusion, three RBC substitute products are undergoing multicenter efficacy trials (Table 1), using avoidance of transfusion as the typical primary end-point [4]. Hopefully, these studies will show the solutions to be safe and effective for use both as volume expanders and as oxygen carriers. The potential benefits to the hemorrhaging trauma patient are immeasurable.
Table 1

Red cell substitutes under active (phase III) investigation

Company

Product

Type

Clinical trial status

Northfield Laboratories

PolyHeme®

Human glutaraldehyde polymerized

Ongoing phase III multicenter trials in North America in vascular and general surgery. Initiating phase III DOD trial in trauma to begin in the prehospital setting

Biopure

Hemopure®: hemoglobin glutamer-bovine

Bovine glutaraldehyde polymerized

Completed phase III multicenter trial USA orthopedic surgery. Biologic license application under review by US Food and Drug Administration. Approved for use in South Africa. Initiating phase III DOD trial in trauma to begin in the prehospital and emergency center settings

Hemosol Inc.

HemoLink™: hemoglobin raffimer

Human O-raffinose polymerized

Completed phase III multicenter trial in coronary bypass patients in Canada and the UK. Planning anemia trials in North America

DOD, Department of Defense.

Abbreviations

RBC: 

RBC = red blood cell.

Declarations

Authors’ Affiliations

(1)
Professor and Chief, Divisions of Trauma and Surgical Critical Care, Daughtry Family Department of Surgery, University of Miami School of Medicine

References

  1. Arias E, Anderson RN, Kung H-C, Murphy SL, Kochanek KD: Deaths: final data for 2001. Natl Vital Stat Rep 2003, 52: 1-115.PubMedGoogle Scholar
  2. Gould SA, Moore EE, Hoyt DB, Ness PM, Norris EJ, Carson JL, Hides GA, Freeman IHG, DeWoskin R, Moss GS: The life-sustaining capacity of human polymerized hemoglobin when red cells might be unavailable. J Am Coll Surg 2002, 195: 445-452. 10.1016/S1072-7515(02)01335-2View ArticlePubMedGoogle Scholar
  3. Gould SA, Moore EE, Hoyt DB, Burch JM, Haenel JB, Garcia J, DeWoskin R, Moss GS: The first randomized trial of human polymerized hemoglobin as a blood substitute in acute trauma and emergent surgery. J Am Coll Surg 1998, 187: 113-120. 10.1016/S1072-7515(98)00095-7View ArticlePubMedGoogle Scholar
  4. Cohn SM: Blood substitutes in surgery. Surgery 2000, 127: 599-602. 10.1067/msy.2000.106462View ArticlePubMedGoogle Scholar
  5. Kjellstrom BT: Blood substitutes: where do we stand today? J Intern Med 2003, 253: 495-497.View ArticlePubMedGoogle Scholar
  6. Hess JR, MacDonald VW, Brinkley WW: Systemic and pulmonary hypertension after resuscitation with cell-free hemoglobin. J Appl Physiol 1993, 74: 1769-1778.PubMedGoogle Scholar
  7. Sharma AC, Singh G, Gulati A: Role of NO mechanism in cardiovascular effects of diaspirin cross-linked hemoglobin in anesthetized rats. Am J Physiol Heart Circ Physiol 1995, 269: H1379-H1388.Google Scholar
  8. Kasper SM, Grune F, Walter M, Amr N, Erasmi H, Buzello W: The effects of increased doses of bovine hemoglobin on hemodynamics and oxygen transport in patients undergoing preoperative hemodilution for elective abdominal aortic surgery. Anesth Analg 1998, 87: 284-291.PubMedGoogle Scholar
  9. Hughes GS Jr, Antal EJ, Locker PK, Francom SF, Adams WJ, Jacobs EE Jr: Physiology and pharmacokinetics of a novel hemoglobin-based oxygen carrier in humans. Crit Care Med 1996, 24: 756-764. 10.1097/00003246-199605000-00006View ArticlePubMedGoogle Scholar
  10. Johnson JL, Moore EE, Offner PJ, Haenel JB, Hides GA, Tamura DY: Resuscitation of the injured patient with polymerized stroma-free hemoglobin does not produce systemic or pulmonary hypertension. Am J Surg 1998, 176: 612-617. 10.1016/S0002-9610(98)00275-XView ArticlePubMedGoogle Scholar
  11. Gould SA, Rosen AL, Sehgal LR, Sehgal HL, Langdale LA, Krause LM, Rice CL, Chamberlin WH, Moss GS: Fluosol-DA as a red-cell substitute in acute anemia. N Engl J Med 1986, 314: 1653-1656.View ArticlePubMedGoogle Scholar
  12. Spahn DR, van Brempt R, Theilmeier G, Reibold JP, Welte M, Heinzerling H, Birck KM, Keipert PE, Messmer K, Heinzerling H, Birck KM, Keipert PE, Messmer K: Perflubron emulsion delays blood transfusions in orthopedic surgery. European Perflubron Emulsion Study Group. Anesthesiology 1999, 91: 1195-1208. 10.1097/00000542-199911000-00009View ArticlePubMedGoogle Scholar

Copyright

© BioMed Central Ltd 2004

Advertisement